US Stock MarketDetailed Quotes
VERA Vera Therapeutics
- 48.310
- +1.280+2.72%
Close Nov 22 16:00 ET
- 48.310
- 0.0000.00%
Post 16:02 ET
3.06BMarket Cap-18509P/E (TTM)
48.940High47.100Low793.05KVolume47.280Open47.030Pre Close38.41MTurnover1.54%Turnover RatioLossP/E (Static)63.32MShares51.61052wk High10.58P/B2.49BFloat Cap12.28052wk Low--Dividend TTM51.51MShs Float51.610Historical High--Div YieldTTM3.91%Amplitude5.200Historical Low48.431Avg Price1Lot Size
Vera Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -60.56%-36.89M | -39.44%-24.78M | -28.67%-33.83M | -36.37%-92.18M | -18.82%-25.14M | -24.72%-22.97M | 6.63%-17.77M | -192.75%-26.29M | -185.12%-67.6M | -228.70%-21.16M |
| Net income from continuing operations | -131.95%-46.63M | -67.19%-33.71M | 5.61%-28.38M | -7.79%-95.99M | 20.91%-25.66M | 18.54%-20.1M | -35.74%-20.16M | -76.00%-30.07M | -173.10%-89.06M | -92.55%-32.44M |
| Depreciation and amortization | 300.00%24K | 189.17%1.5M | -190.32%-1.47M | -382.98%-4.09M | -587.27%-4.1M | 103.95%6K | 587.74%517K | -5,722.22%-506K | -580.68%-846K | -1,965.63%-597K |
| Other non cash items | 11.94%703K | 23.99%889K | -10.71%517K | -62.07%2.22M | -42.97%300K | -85.13%628K | 30.13%717K | 2.66%579K | 46.54%5.86M | -89.21%526K |
| Change In working capital | 219.68%5.86M | 5,242.61%6.14M | -931.15%-8.62M | -186.99%-5.87M | -124.86%-2.12M | -953.55%-4.9M | 101.60%115K | -82.33%1.04M | 92.17%6.75M | 98.88%8.54M |
| -Change in prepaid assets | 11.69%-1.84M | 218.36%2.72M | -110.46%-392K | 102.11%173K | 267.84%809K | -1,255.19%-2.09M | 36.24%-2.3M | 195.10%3.75M | -254.81%-8.18M | -168.27%-482K |
| -Change in payables and accrued expense | 468.51%8M | 20.49%4.03M | -274.70%-7.6M | -117.50%-3.09M | -122.99%-2.24M | -640.30%-2.17M | 226.34%3.35M | -119.95%-2.03M | 200.65%17.64M | 167.36%9.72M |
| -Change in other current assets | 2,809.09%320K | 104.81%13K | 325.00%9K | -178.38%-309K | -253.85%-46K | 116.67%11K | 10.89%-270K | -101.48%-4K | -117.65%-111K | 74.51%-13K |
| -Change in other current liabilities | 5.07%-618K | 6.32%-623K | 6.32%-637K | -1.65%-2.65M | 6.35%-649K | -0.62%-651K | -4.56%-665K | -8.63%-680K | ---2.6M | ---693K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -60.56%-36.89M | -39.44%-24.78M | -28.67%-33.83M | -36.37%-92.18M | -18.82%-25.14M | -24.72%-22.97M | 6.63%-17.77M | -192.75%-26.29M | -185.12%-67.6M | -228.70%-21.16M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 136.12%38.32M | 73.77%-22.68M | -1,892.43%-219.29M | 44.11%-39.43M | 38.10%18.56M | 765.08%16.23M | -105.37%-86.45M | 131.01%12.23M | -1,578.21%-70.55M | 368.74%13.44M |
| Net PPE purchase and sale | ---238K | ---- | ---- | -1.61%-63K | ---63K | --0 | ---- | ---- | ---62K | --0 |
| Net investment purchase and sale | 137.58%38.56M | 73.87%-22.59M | -1,892.43%-219.29M | 44.15%-39.37M | 38.57%18.62M | 775.60%16.23M | -105.40%-86.45M | 131.02%12.23M | ---70.49M | --13.44M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 136.12%38.32M | 73.77%-22.68M | -1,892.43%-219.29M | 44.11%-39.43M | 38.10%18.56M | 765.08%16.23M | -105.37%-86.45M | 131.01%12.23M | -1,578.21%-70.55M | 368.74%13.44M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 148.82%739K | 696.06%3.44M | 156.09%276.54M | 31.01%133.54M | 19.89%24.83M | -67.29%297K | 800.00%432K | 34.53%107.98M | 89.18%101.93M | 320.83%20.71M |
| Net issuance payments of debt | ---- | ---- | ---- | 24.85%24.74M | ---- | ---- | ---- | ---- | 302.68%19.82M | ---- |
| Net common stock issuance | ---13K | --0 | 150.03%287.54M | 33.52%115M | --0 | --0 | --0 | 33.52%115M | 68.30%86.13M | ---1K |
| Proceeds from stock option exercised by employees | 153.20%752K | 696.06%3.44M | 2,779.58%6.91M | -49.30%1.06M | -89.48%87K | -69.54%297K | 819.15%432K | 2.56%240K | 278.73%2.08M | --827K |
| Net other financing activities | --0 | --0 | -146.80%-17.91M | -19.01%-7.26M | --0 | --0 | --0 | -19.03%-7.26M | -120.51%-6.1M | --67K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 148.82%739K | 696.06%3.44M | 156.09%276.54M | 31.01%133.54M | 19.89%24.83M | -67.29%297K | 800.00%432K | 34.53%107.98M | 89.18%101.93M | 320.83%20.71M |
| Net cash flow | ||||||||||
| Beginning cash position | -25.98%25.09M | -49.81%69.11M | 4.41%45.68M | -45.29%43.75M | -10.81%27.44M | -33.18%33.89M | 23.15%137.68M | -45.29%43.75M | 48.10%79.97M | -64.42%30.77M |
| Current changes in cash | 133.67%2.17M | 57.59%-44.02M | -75.06%23.42M | 105.33%1.93M | 40.48%18.24M | 67.68%-6.45M | -69.93%-103.79M | 195.07%93.93M | -239.45%-36.22M | 299.23%12.98M |
| End cash Position | -0.67%27.26M | -25.98%25.09M | -49.81%69.11M | 4.41%45.68M | 4.41%45.68M | -10.81%27.44M | -33.18%33.89M | 23.15%137.68M | -45.29%43.75M | -45.29%43.75M |
| Free cash flow | -61.59%-37.12M | -39.94%-24.87M | -28.67%-33.83M | -36.34%-92.24M | -19.11%-25.21M | -24.46%-22.97M | 6.65%-17.77M | -192.17%-26.29M | -185.38%-67.66M | -228.70%-21.16M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data